Literature DB >> 12682788

A new animal model for the imaging of melanoma: correlation of FDG PET with clinical outcome, macroscopic aspect and histological classification in Melanoblastoma-bearing Libechov Minipigs.

Raphaël Boisgard1, Silvia Vincent-Naulleau, Jean-Jacques Leplat, Stephan Bouet, Catherine Le Chalony, Yves Tricaud, Vratislav Horak, Claudine Geffrotin, Gérard Frelat, Bertrand Tavitian.   

Abstract

The aim of this study was to evaluate the Melanoblastoma-bearing Libechov Minipigs (MeLiM) as an animal model of melanoma for in vivo imaging. Serial whole-body 2-deoxy-2-[(18)F]fluoro- d-glucose positron emission tomography (FDG PET) scans were conducted on five MeLiM. In order to explore different clinical stages of the tumoural lesions, each animal was scanned two to four times, at intervals of 30-155 days. PET images were analysed by a semiquantitative method based on the tumour to muscle metabolic ratio. Histology was performed on biopsies taken between or after the scans and the histological grading of the tumours was compared with the FDG uptake. The overall sensitivity of FDG PET for the detection of cutaneous melanoma was 75%; 62.5% of involved lymph nodes were positive. Sensitivity was better for tumours with vertical growth than for flat lesions. FDG PET did not detect tumours with epidermal involvement only, nor did it detect small metastatic foci. The metabolic ratio was correlated with the evolution of the melanoma. FDG PET is effective in the staging of cutaneous melanoma and the follow-up of tumoural extension and regression in Melanoblastoma-bearing Libechov Minipigs. The results obtained in this animal model correlate well with those described in human melanoma. Accordingly, this model may be useful in testing new tracers specific for melanoma and in helping to detect molecules expressed early during tumoural regression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682788     DOI: 10.1007/s00259-003-1152-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  32 in total

1.  Response of Osteosarcoma to Chemotherapy. Evaluation with F-18 FDG-PET Scans.

Authors: 
Journal:  Clin Positron Imaging       Date:  2000-03

2.  Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma.

Authors:  K M Acland; C Healy; E Calonje; M O'Doherty; T Nunan; C Page; E Higgins; R Russell-Jones
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

3.  The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma.

Authors:  H Jadvar; D L Johnson; G M Segall
Journal:  Clin Nucl Med       Date:  2000-01       Impact factor: 7.794

4.  Positron emission tomography in the detection and management of metastatic melanoma.

Authors:  D L Damian; M J Fulham; E Thompson; J F Thompson
Journal:  Melanoma Res       Date:  1996-08       Impact factor: 3.599

5.  Hereditary melanoblastoma in miniature pigs and its successful therapy by devitalization technique.

Authors:  V Horák; K Fortýn; V Hruban; J Klaudy
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1999-11       Impact factor: 1.770

Review 6.  Emerging concepts and technologies in melanoma research.

Authors:  M Herlyn
Journal:  Melanoma Res       Date:  2002-02       Impact factor: 3.599

Review 7.  Cutaneous malignant melanoma: clinical aspects, imaging modalities and treatment.

Authors:  I Ak; M P Stokkel; W Bergman; E K Pauwels
Journal:  Eur J Nucl Med       Date:  2000-04

8.  Complete regression of primary cutaneous malignant melanoma.

Authors:  S W Menzies; W H McCarthy
Journal:  Arch Surg       Date:  1997-05

9.  Positron emission tomography scanning in malignant melanoma.

Authors:  D S Tyler; M Onaitis; A Kherani; A Hata; E Nicholson; M Keogan; S Fisher; E Coleman; H F Seigler
Journal:  Cancer       Date:  2000-09-01       Impact factor: 6.860

10.  Malignant melanoma in the Sinclair miniature swine: an autopsy study of 60 cases.

Authors:  R W Oxenhandler; E H Adelstein; J P Haigh; R R Hook; W H Clark
Journal:  Am J Pathol       Date:  1979-09       Impact factor: 4.307

View more
  5 in total

1.  Use of ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography in a miniature pig (Sus scrofa domestica) with pneumonia.

Authors:  Jong-In Kim; Young Ah Lee; Jae Won Lee; Sang Min Jeong; Hyun Woo Chung; Jin Soo Han
Journal:  Comp Med       Date:  2012-06       Impact factor: 0.982

Review 2.  Animal models and molecular imaging tools to investigate lymph node metastases.

Authors:  Elliot L Servais; Christos Colovos; Adam J Bograd; Julie White; Michel Sadelain; Prasad S Adusumilli
Journal:  J Mol Med (Berl)       Date:  2011-05-10       Impact factor: 4.599

3.  In vivo follow-up of rat tumor models with 2-deoxy-2-[F-18]fluoro-D-glucose/dual-head coincidence gamma camera imaging.

Authors:  Jacques Monteil; Aurélie Dutour; Barbara Akla; Thierry Chianéa; Valérie Le Brun; Laurent Grossin; François Paraf; Yolande Petegnief; Jean-Claude Vandroux; Michel Rigaud; Franck G Sturtz
Journal:  Mol Imaging Biol       Date:  2005 May-Jun       Impact factor: 3.488

4.  Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model.

Authors:  Christiane Franzius; Marc Hotfilder; Christopher Poremba; Sven Hermann; Klaus Schäfers; Helmut Erich Gabbert; Heribert Jürgens; Otmar Schober; Michael Schäfers; Josef Vormoor
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-29       Impact factor: 10.057

5.  Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β+ T Cells and Differentiated γδ T Cells Alongside a Regulatory Response Mediated by FOXP3+ T Cells and Immunoregulatory Molecules.

Authors:  Nana H Overgaard; Daniel R Principe; Kyle M Schachtschneider; Jeanne Toft Jakobsen; Laurie A Rund; Paul J Grippo; Lawrence B Schook; Gregers Jungersen
Journal:  Front Immunol       Date:  2018-06-07       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.